NCT03714334View on ClinicalTrials.gov

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

April 5, 2023

Study Completion Date

April 5, 2023

Conditions

GlioblastomaGlioblastoma, Adult

Interventions

DRUG

DNX-2440 injection

DNX-2440 virus will be injected stereotactically

Trial Locations (1)

31008

Clinica Universidad de Navarra, Pamplona

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

DNAtrix, Inc.

INDUSTRY

lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER

NCT03714334 - DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter